Interpretation of updated domestic and foreign guidelines on menopause management and menopausal hormone therapy
HUANG Feiling
CHEN Rong
Abstract：Menopause is a landmark event of ovarian failure.During the process of ovarian failure,the fluctuating decline levels and deficiency of estrogen can lead to a series of menopausal symptoms and increase the risk of many metabolic diseases,having a significant impact on the affected women's long-term health risks and quality of life.Menopause management needs the prevention of long-term chronic diseases while alleviating menopause-related symptoms.Between 2023 and 2024,the Menopausal Study Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association,the International Federation of Gynecology and Obstetrics(FIGO),and the International Menopause Society(IMS)successively released Chinese Guidelines for Menopause Management and Menopausal Hormone Therapy,2023 Edition,the FIGO Position Statement:How to Explain the Advantages and Disadvantages of Menopausal Hormone Therapy for Postmenopausal Women and the 2024 White Paper of the International Menopause Society on Core Disputes of Menopa use and Menopausal Hormone Therapy,which are 3 papers of important literature on menopause and menopausal hormone therapy.This paper conducts a comprehensive interpretation based on the core points of the above three papers,with the aim of helping clinicians understand the progress of the discipline and better manage,prevent and treat menopause-related symptoms and diseases.
Keywords：MenopauseMenopausal hormone therapyGuidelineFIGO position statementInternational Menopause Society White PaperInterpretation
Publication Date：2025-05-30
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 476-480 )